Standout Papers

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safe... 2010 2026 2015 2020 2.3k
  1. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (2010)
    Julie R. Brahmer, Charles G. Drake et al. Journal of Clinical Oncology
  2. In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates (2014)
    Changyu Wang, Kent Thudium et al. Cancer Immunology Research

Immediate Impact

30 by Nobel laureates 61 from Science/Nature 95 standout
Sub-graph 1 of 17

Citing Papers

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
2018 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
19 intermediate papers

Works of Mark Selby being referenced

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
2015
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
2010 Standout
and 2 more

Author Peers

Author Last Decade Papers Cites
Mark Selby 3172 2990 3378 94 9.4k
Fernando Arenzana‐Seisdedos 7029 4997 6201 93 16.6k
Thomas Bugge 1597 4444 1874 165 11.1k
David Buck 3008 3637 2438 65 9.0k
Shoshana Levy 4238 3831 1291 136 11.2k
Arie Abo 2566 8605 4224 56 14.9k
Hongkui Deng 3401 8308 1364 167 15.7k
Victor Koteliansky 2988 10158 1734 125 16.9k
Stephen C. Peiper 6609 4249 4232 178 13.9k
Stephen Shaw 9884 3704 2264 168 16.3k
Claude Boucheix 2138 3919 1096 178 9.9k

All Works

Loading papers...

Rankless by CCL
2026